Completed OBSERVATIONAL NCT02435147

Longitudinal Effects of Denosumab on Trabecular Bone Score and Femur Strength Index

Sponsor: Amgen

Interventions denosumab

Updated 9 times since 2017 Last updated: Oct 26, 2018 Started: Apr 30, 2015 Primary completion: Jun 30, 2016 Completion: Jun 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02435147, this observational or N/A phase trial focuses on Bone Fracture and Osteoporosis and remains completed. Sponsored by Amgen, it has been updated 9 times since 2015, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Dec 2021 — Jul 2024 [monthly]

Completed
Jan 2021 — Dec 2021 [monthly]

Completed
Nov 2018 — Jan 2021 [monthly]

Completed

▶ Show 4 earlier versions

Jun 2018 — Nov 2018 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: NA → None
Feb 2017 — Apr 2018 [monthly]

Completed NA
Jan 2017 — Feb 2017 [monthly]

Completed NA

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
HealthEast Care System

Data source: HealthEast Care System

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Saint Paul, United States